Insider Transactions in Q1 2025 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2025
|
Todd C Davis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,382
+12.35%
|
-
|
|
Mar 04
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,484
+22.11%
|
-
|
|
Mar 04
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-20.94%
|
$575,000
$115.03 P/Share
|
|
Mar 04
2025
|
Andrew Reardon CLO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
6,415
+15.57%
|
-
|
|
Feb 15
2025
|
Todd C Davis Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,486
-2.4%
|
$778,320
$120.0 P/Share
|
|
Feb 15
2025
|
Andrew Reardon CLO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,990
-3.33%
|
$238,800
$120.0 P/Share
|
|
Feb 15
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,027
-3.9%
|
$363,240
$120.0 P/Share
|
|
Feb 14
2025
|
Todd C Davis Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,966
-4.84%
|
$835,920
$120.0 P/Share
|
|
Feb 14
2025
|
Todd C Davis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,784
+12.63%
|
-
|
|
Feb 14
2025
|
Andrew Reardon CLO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
4,533
-7.45%
|
$543,960
$120.0 P/Share
|
|
Feb 14
2025
|
Andrew Reardon CLO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
12,357
+16.75%
|
-
|
|
Feb 14
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,560
-11.48%
|
$787,200
$120.0 P/Share
|
|
Feb 14
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,819
+18.31%
|
-
|